Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on ContraVir Pharmaceuticals, Inc.

by

Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.

ContraVir Pharmaceuticals is a U.S. public bio/pharmaceutical company that develops and commercializes targeted antiviral therapies for the treatment of Hepatitis B, shingles and shingles pain. It plans to raise $12 million in a secondary public offering, as reported in the PharmSource Lead Sheet on April 27, 2017.

Corporate Highlights

  • ContraVir Pharmaceuticals was incorporated in Delaware on May 15, 2013
  • Corporate Headquarters: Edison, NJ – approximately 4,000 square feet of office and laboratory space
  • Research & Development Facility: Edmonton, AB, Canada
  • As of January 31, 2017, they had 65 employees
  • Stock Exchange: NASDAQ
  • Stock Symbol: CTRV

Sourcing Opportunities

  • ContraVir Pharmaceuticals plans to use the proceeds to fund R&D activities and ongoing clinical trials of its pipeline, which may include:
    • CRV431 – To complete IND-enabling studies:
      • For treatment of Hepatitis B
      • Dosage Form: Oral
      • Nature of API: Chemical – Normal potency
      • Therapeutic Areas: Antiviral; Liver disease
  • TXL (Formerly CMX157) – To complete a Phase II study:
    • For treatment of Hepatitis B
    • Dosage Form: Tablet
    • Nature of API: Chemical – Normal potency
    • Therapeutic Areas: Antiviral; Liver disease
  • The company contracts with contract research organizations (CROs) to conduct ongoing and planned clinical trials.
  • ContraVir Pharmaceuticals currently does not own or operate any manufacturing facilities and relies on third party contract manufacturers for all required raw materials, API and finished product for preclinical studies and clinical trials.
  • ContraVir Pharmaceuticals has no sales, marketing and distribution capabilities.
  • Business Relationships

    • December 18, 2014, ContraVir Pharmaceuticals and Chimerix entered into a licensing agreement for ContraVir Pharmaceuticals to further the clinical development and commercialization of CMX157 for the treatment of Hepatitis B. Under the terms of the agreement, Chimerix received an upfront payment of $1.2 million with up to $20 million in milestone and commercial milestones.1

    Drug Product Pipeline

    Product Candidate Indication Dosage Form Status Next Anticipated Step
    CRV431 Hepatitis B Oral Preclinical TBA
    TXL Hepatitis B Tablet Phase II TBA
    Valnivudine Nerve pain associated with shingles Oral Phase III TBA

    Finances

    (In $ thousands) 2016 2015
    Revenues
    R&D Expenditures
    15,019,277
    8,403,579
    General & Administrative Expenditures
    5,786,208
    5,556,400
    Total Operating Expenses
    20,805,485
    13,959,979

    1ContraVir Pharmaceuticals, Inc. 9/28/16 10-K, SEC.gov

    Contact Information

    ContraVir Pharmaceuticals, Inc. Key Officers
    399 Thronall Street, First Floor James Sapirstein, CEO
    Edison, NJ, 08837 USA Robert Foster, PhD, CSO
    Phone: +1-732-902-4000 John Sullivan-Bolyai, MD, CMO
    Fax: +1-732-902-4100 Michael A. Conover, Manager, Clinical Trials
    Web: www.contravir.com Theresa Matkovits, PhD, SVP, Drug Development

    Related posts:
    Follow the Money to Pharmaceutical Opportunities – Spotlight on BioCryst Pharmaceuticals, Inc.
    Follow the Money to Pharmaceutical Opportunities – Spotlight on Aldeyra Therapeutics, Inc.
    Follow the Money to Pharmaceutical Opportunities – Spotlight on Zynerba Pharmaceuticals, Inc.

    Scotty is a Research Analyst at PharmSource. He holds a BS degree in Biology from George Mason University and an MPH degree from Eastern Virginia Medical School. He’s experienced in data collection, analysis and management, and has done laboratory analysis and safety program development.

    More posts by Scotty Chung-Siu